Skip to content

SELFPHARMA

Active Private limited companyfounded 2008active for 18 yearsBaraplein 2, 1070 AnderlechtKBO/BCE: BE 0806.621.811
SELFPHARMA
Follow ReportCompare

Overview

Lifetime

15 annual accounts with figures on one time axis
peak €357,114 (2023)
€350,855 
peak €75,599 (2022)
€50,557 
peak €713,435 (2025)
€713,435 
€643,572 
peak 6.4 FTE (2019)
-not published
Board1 name since 2008
1 director
Documentsfilings and deeds
11-10-202672 days late
2025abbreviated format
No annual accounts filed for 2024

Key points

from the 2025 annual accounts

Equity

€713,435

SELFPHARMA has made a profit in every financial year since 2009.

Staff

4.6 FTE from 6.4 in 2019

Between 2019 and 2025, 28% of the full-time equivalents disappeared.

Filings

15 annual accounts 72 days
AprilJune31 JulyOctober2010201520202025

Latest accounts filed late: after the legal deadline.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 10,902 companies had the same profile as SELFPHARMA has now. Each dot stands for 28 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit under 5% of the balance sheet
Test of the method

The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 10,902 companies, not a prediction for SELFPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 26-09-2008
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0806621811
Reappointment: (sole director) General meeting of 22-02-2024 · Gazette deed
Company renamed from CITYPHARMA to SELFPHARMA General meeting of 09-12-2016 · Gazette deed
First establishment CITYPHARMA, Baraplein 2, Anderlecht
All 26 events

Comparable companies

same main activity, similar in size and age
Company
SELFPHARMA Anderlecht €1.4m €350,855 52.6% -
APOTHEEK MORTELMANS Heist-op-den-Berg €1.4m €340,265 67.0% -
APOTHEKER STEVEN VRIJDAG Dendermonde €1.3m €326,784 47.0% 0.9
PEP PHARMA Pepinster €1.3m €326,063 36.4% 1.6
PHARMACIE DU GROS FAYT Courcelles €1.2m €340,808 61.9% 2
PHARMACIE DE LA VESDRE Verviers €1.4m €302,084 42.2% -
DE LA DREVE Waterloo €1.4m €312,374 25.9% 2.6

These companies have the same main activity as SELFPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.2m and €1.4m, founded between 2007 and 2010.

Official details

Source: KBO
Status
Active since 26-09-2008Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.173.692.3011070 Anderlecht, since 01-10-2008
Financial year end
31 December
Peppol
Reachable since 13-10-2025
Company details

Annual accounts 2025

€350,855
≈ €1.3mestimated
€50,557
€713,435
€1.4m
Employeeson 31-12-2025
5
Filing
Filed on 11-10-2026
Financials

Insights on SELFPHARMA

SELFPHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €186,937 in 2009 to €350,855 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 11-10-2026, 72 days late
€350,855
€74,664
€50,557
€787,905
52.6%
4.53

The turnover shown is an estimate from the gross margin.

Turnover ≈ €1.3m. Estimated: probably between €950,000 and €2.0m.

Balance sheet

balance sheet total €1.4m on 31-12-2025
What the company ownsHow it is paid for

Position in the sector

Compare with sector

52.6%

Higher than 67% of 13,234 companies in 2025.

4.53

Higher than 87% of 13,093 companies in 2025.

3.7%

Higher than 46% of 13,156 companies in 2025.

SELFPHARMA Middle half of the sector 80% of the sector Abbreviated accounts in retail trade (NACE 47)

Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: top quarter · Staff: middle half

Staff

€48,446

Staff costs divided by the average number of full-time equivalents.

people who joined people who left

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252023202220202019201820172016201520142013201220112010200915 months
Balance sheet: assets
20/58 1.4m1.3m1.2m922,628711,709751,128727,449733,070734,666638,787437,227548,681516,201524,102619,732
21/28 345,755301,349233,615234,974201,543229,718287,254335,173339,434368,465145,252191,806239,316291,072341,145
21 ------24,80049,60074,40099,200124,000148,800173,600198,400223,200
22/27 345,530301,124233,390234,749201,318229,493262,229285,348264,809269,04021,02742,78165,49192,672117,945
22 117,000130,000143,000169,000182,000195,000208,000221,000234,000247,000-----
23 23,969162,38675,38465,7496531,0016601,1902,4313,0222,1334,2042,7204,0805,440
24 508,73815,006-18,66433,49153,56963,15828,37819,01818,89438,57762,77188,592112,505
26 204,511--------------
28 225225225225225225225225225225225225225--
29/58 1.0m956,495965,369687,654510,166521,411440,195397,896395,231270,322291,975356,875276,885233,029278,587
29 472,000472,000560,000------------
291 472,000472,000560,000------------
3 127,559162,096169,27360,60530,85940,42236,06552,08558,44660,15172,24482,464117,033102,296108,642
30/36 127,559162,096169,27360,60530,85940,42236,06552,08558,44660,15172,24482,464117,033102,296108,642
40/41 238,663198,341103,678441,048410,029341,160277,306257,019265,335121,781150,044155,97961,70063,49062,077
40 132,649166,95186,94085,71176,02475,78268,93491,383119,96144,58274,26060,84957,51650,38551,970
41 106,01531,39116,738355,337334,005265,377208,373165,636145,37477,19975,78495,1314,18313,10510,107
54/58 167,028117,875128,486183,46969,278139,829126,82488,79371,45188,39069,687118,43198,15267,243105,567
490/1 6,0026,1833,9312,533----------2,300
Balance sheet: equity and liabilities
10/49 1.4m1.3m1.2m922,628711,709751,128727,449733,070734,666638,787437,227548,681516,201524,102619,732
10/15 713,435632,807596,253365,010319,108255,988224,484182,688157,928116,961107,153182,644131,14075,77151,500
10/11 20,46018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,600
10 -18,60018,600------------
100 -18,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,600
13 166,500123,360123,360346,410300,508237,388205,884164,088139,32898,36188,553164,044112,54057,17132,900
130/1 166,500123,360123,3601,860-----------
130 -1,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,860
1311 166,500121,500121,500------------
133 ---344,550298,648235,528204,024162,228137,46896,50186,693162,184110,68055,31131,040
14 526,475490,847454,293------------
17/49 643,572625,036602,731557,619392,601495,140502,965550,382576,738521,826330,074366,037385,061448,330568,232
17 420,225410,035294,818282,900215,510227,430276,672322,226314,934350,531166,441199,092235,494270,912303,022
170/4 420,225410,035294,818282,900215,510227,430276,672322,226314,934350,531166,441199,092235,494270,912303,022
42/48 223,347215,001307,913274,719177,091267,711226,293228,156261,804171,295163,632166,944149,567177,418265,209
42 20,4453,8513,78072217,78855,04545,58944,98634,74730,61132,26436,40235,41834,41332,923
43 ---50,000-50,000---------
430/8 ---50,000-50,000---------
44 133,266178,993194,245144,24876,228109,960135,429125,037168,665107,64197,30081,31153,88452,54262,997
440/4 133,266178,993194,245144,24876,228109,960135,429125,037168,665107,64197,30081,31153,88452,54262,997
45 69,63632,156109,88879,74983,07452,70645,27558,13258,39233,04334,06949,23238,73410,87213,922
450/3 21,4365,75384,12442,10231,1517,41918,89836,43237,27225,89629,46338,93734,02710,72613,922
454/9 48,20026,40425,76437,64751,92445,28726,37721,70121,1207,1474,60610,2954,707147-
47/48 ------------21,53179,591155,367
Income statement
76A --16,26838,424--7,8098,145-3,10316,923---21,802
9900 350,855357,114328,903237,667313,733303,653289,640263,855280,889259,477237,048254,120267,499195,613186,937
62 222,852233,232183,911145,906175,349167,878144,710150,774145,990134,144100,282111,582116,72291,63997,757
630 48,88029,37427,67719,33133,77359,72161,09960,07352,55554,45088,70854,26452,91352,69052,166
640/8 4,4598,7129,5678,4147,0868,9026,5598,1796,1615,3396,1258,7338,9715,42710,005
66A ---22,637-9,000----17,017----
9901 74,66485,796107,74764,01697,52458,15277,27344,82976,18465,54441,93379,54188,89345,85827,008
75/76B 10,0001,75420,40038,424-227,8098,1581552395018973271349
75 10,0001,75420,400--22-141552395018973271349
76B ---38,424--7,8098,145-------
65/66B 18,50923,66820,98937,88715,68716,78424,51215,78413,73812,0906,5417,57310,3209,0422,173
65 18,50923,66820,98915,25015,68716,78424,51215,78413,73812,0906,5417,57310,3209,0422,173
66B ---22,637-----------
9903 66,15563,883107,15964,55481,83741,38960,57037,20462,60156,79535,79972,86478,90036,82846,686
67/77 15,59827,32931,56018,65218,7179,88518,77412,44421,63416,98711,29021,36023,53210,15613,786
9904 50,55736,55475,59945,90163,12031,50441,79624,76040,96739,80824,50951,50555,36826,67132,900
9905 50,55736,55475,59945,90163,12031,50441,79624,76040,96739,80824,50951,50555,36826,67132,900
Appropriation of the result
9906 576,475490,847529,89245,90163,12031,50441,79624,76040,96739,80824,50951,50555,36826,67132,900
14P 525,918454,293454,293------------
791/2 ----------75,491----
691/2 50,000-75,59945,90163,12031,50441,79624,76040,9679,808-51,50555,36824,27132,900
6920 --------------1,860
6921 50,000-75,59945,90163,12031,50441,79624,76040,9679,808-51,50555,36824,27131,040
694/7 ---------30,000100,000--2,400-
694 ---------30,000100,000--2,400-
Social balance sheet
9087 4.65.155.86.44.74.44.54.34.72.62.732.83
Hours worked1013 7,1547,9136,9637,7489,7178,4337,0926,8016,5046,7134,1584,3094,3374,9094,268
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The notes to these accounts have 14 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 11-10-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 abbreviated format 11-10-2026 2026-00553393 PDF
31-12-2023 full format 30-08-2024 2024-00410851 PDF
31-12-2022 micro format 24-04-2024 2024-00067798 PDF
31-12-2020 full format 29-10-2021 2021-75800239 PDF
31-12-2019 full format 30-09-2020 2020-57500558 PDF
31-12-2018 full format 28-09-2019 2019-67300270 PDF
31-12-2017 full format 27-09-2018 2018-65900376 PDF
31-12-2016 full format 29-09-2017 2017-64800310 PDF
31-12-2015 full format 27-10-2016 2016-66700426 PDF
31-12-2014 full format 30-09-2015 2015-63300554 PDF
31-12-2013 full format 19-09-2014 2014-59700175 PDF
31-12-2012 full format 27-09-2013 2013-61000347 PDF
31-12-2011 full format 28-08-2012 2012-47300263 PDF
31-12-2010 full format 08-07-2011 2011-28400573 PDF
31-12-2009 full format 20-08-2010 2010-44200519 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252023202220202019201820172016201520142013201220112010200915 months
123,544115,170135,42583,347131,297117,873138,372104,902128,739119,994130,641133,805141,80698,54779,175
99,43765,928103,27665,23396,89391,225102,89584,83393,52294,258113,217105,769108,28179,36185,066
36,99897,107-67,9005,5982,18513,17955,81223,524277,66442,1546,7541,1572,617393,311
--10,610-114,191-70,55113,00538,03217,342-16,93918,702-48,74420,28030,909-38,325-
787,905741,494657,456412,935333,075253,700213,903169,741133,42799,027128,343189,931127,31855,61113,377
52.6%50.3%49.7%39.6%44.8%34.1%30.9%24.9%21.5%18.3%24.5%33.3%25.4%14.5%8.3%
4.534.453.142.502.881.951.951.741.511.581.782.141.851.311.05
3.963.692.592.282.711.801.791.521.291.231.341.641.070.740.64
0.900.991.011.531.231.932.243.013.654.463.082.002.945.9211.03
7.1%5.8%12.7%12.6%19.8%12.3%18.6%13.6%25.9%34.0%22.9%28.2%42.2%35.2%63.9%
3.7%2.9%6.3%5.0%8.9%4.2%5.7%3.4%5.6%6.2%5.6%9.4%10.7%5.1%5.3%
6.674.876.45------------

EBIT margin: not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202331-12-2022
Employees at the balance-sheet date566
full-time343
part-time223
in full-time equivalents4.65.65.1
4.65.15
On a permanent contract555
Joined-22
Left-20

Source: social balance sheet in the 2022 to 2025 annual accounts

Investments

fixed assets acquired
Item202520232022
Tangible fixed assets€36,998€97,107-
€48,880€29,374€27,677

Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)

Insights on SELFPHARMA

The operating result for 2025 is €74,664, against €85,796 in 2023. Comparable figures for the intervening years are unavailable.

Debt's share of the balance-sheet total is 47.4%.

Board & ownership

Board

1 director
Sole director
since 26-09-2008 term without a fixed end
listed in the 2025 annual accounts

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today

Sole director
Board
Mandates as a list
    • Sole director, from 25-09-2008 to date

See the board, name and registered office on a given date →

Control

See the annual accounts at the National Bank and the publications in the Belgian Official Gazette.

Capital

Contribution
€20,460
Shares
200
Contribution per share
€102
Equity per share
€3,567 in 2025
Source
2025 annual accounts

Articles of association

deed of 29-03-2024 (in French)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
First Monday of June

Network & group

No group

SELFPHARMA has no parent and no holdings in its annual accounts. is the only director. SELFPHARMA shares no director with another company.

At the same address

Baraplein 2, 1070 Anderlecht · 2 other companies
Courier, Sung (sole trader)
establishment since 07-04-2025
 founded in 2025
1022.263.895
Association des copropriétaires à Anderlecht Place Bara 2-3
registered office since 21-12-2011
 founded in 2011
0842.193.590

Timeline

Timeline

26 events since 2008

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed NBBabbreviated format · 72 days late
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0806621811
2024
Annual accounts 2023 filed PDFfull format · 30 days late
Annual accounts 2022 filed PDFmicro format · 268 days late
Reappointment: (sole director)General meeting of 22-02-20245 points ▸
  • General meeting, 22-02-2024
  • 200 shares
  • Director reappointment, (sole director)
  • Registered office clause, place Bara 2, 1070 Anderlecht
  • Power of attorney,
  • The deed holds 2 more points.

Open the deed in the Belgian Official Gazette

2022
Highest result from 2009 to 2025 net €75,599 ▲64.7% The operating result of €107,747 and the net result of €75,599 are both a record.
Equity above €500,000 equity €596,253 ▲63.4% Equity rises from €365,010 to €596,253.
2021
Annual accounts 2020 filed PDFfull format · 90 days late
2020
Annual accounts 2019 filed PDFfull format · 61 days late
2019
Annual accounts 2018 filed PDFfull format · 59 days late
2018
Annual accounts 2017 filed PDFfull format · 58 days late
2017
Equity above €200,000 equity €224,484 ▲22.9% Equity rises from €182,688 to €224,484.
Annual accounts 2016 filed PDFfull format · 60 days late
Company renamed from CITYPHARMA to SELFPHARMAGeneral meeting of 09-12-20165 points ▸
  • General meeting, 09-12-2016
  • 200 shares
  • Name change, SELFPHARMA
  • Amendment of the articles, article 1
  • Power of attorney,
  • The deed holds 7 more points.

Open the deed in the Belgian Official Gazette

2016
Annual accounts 2015 filed PDFfull format · 88 days late
2015
Annual accounts 2014 filed PDFfull format · 61 days late
2014
Annual accounts 2013 filed PDFfull format · 50 days late
2013
Weakest financial year net €24,509 ▼52.4% The net result drops to €24,509, the lowest from 2009 to 2025. It recovers the following year.
Annual accounts 2012 filed PDFfull format · 58 days late
2012
Equity above €150,000 equity €182,644 ▲39.3% With a profit in every financial year since 2009, equity grows to €182,644.
Annual accounts 2011 filed PDFfull format · 28 days late
2011
Equity above €100,000 equity €131,140 ▲73.1% With a profit in every financial year since 2009, equity grows to €131,140.
Annual accounts 2010 filed PDFfull format · 23 days before the deadline
2010
Annual accounts 2009 filed PDFfull format · 20 days late
2008
First establishment CITYPHARMA, Baraplein 2, Anderlecht
Incorporation PDFpublished on 06-10-2008

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

SELFPHARMA was incorporated on 26 September 2008.1 In 2017 the company took the name SELFPHARMA.2 Total assets rose from €751,128 in 2018 to €1.4m in 2025 and headcount from 4.7 to 4.6 full-time equivalents.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 17-02-2017
  3. 3National Bank, annual accounts 2018 and 2025

Company details

Identity

Enterprise number
0806.621.811
VAT number
BE 0806.621.811
Peppol ID
0208:0806621811
Legal form
Private limited company
Status
Active, normal situation
Founded
26-09-2008
Financial year
ends on 31 December
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
First Monday of June
deed of 29-03-2024 (in French)
Peppol
Reachable since 13-10-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
SELFPHARMA in French
Former name
CITYPHARMA until the deed of 17-02-2017
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 29-03-2024 (in French)
Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Région de Bruxelles-Capitale”
deed of 29-03-2024 (in French)

Activities

NACEBEL 2025
VAT activities
47730 Retail sale of pharmaceutical products main activity
Social security (RSZ) activities
47730 Retail sale of pharmaceutical products main activity
Codes under NACEBEL 2008
VAT activities
47730 Retail trade main activity
Social security (RSZ) activities
47730 Retail trade main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
“Toutes opérations financières,mobilières et immobilières,se rapportant à la production,l’achat,la vente,l’importation,l’exportation,la…”
11 activities
  1. Toutes opérations financières,mobilières et immobilières,se rapportant à la production,l’achat,la vente,l’importation,l’exportation,la distribution de substances,produits et services présentés comme possédant des propriétés curatives ou préventives à l’égard des maladies humaines,animales ou végétales,et visant au rétablissement,au maintien ou à l’amélioration de la santé,pour son compte et pour compte de tiers,Belgique et étranger
  2. A)des officines pharmaceutiques dans lesquelles s’effectue la vente de médicaments ainsi que d’articles de toilette et d’hygiène,de parfumerie,de diététique,de cosmétologie,de dermatologie et de bandagisterie
  3. B)des établissements qui fournissent des produits et des services en matière d’optique,de bandagisterie,d’orthopédie,de prothèse,d’audiométrie,de fournitures dentaires,de matériel médical et des accessoires,et tous autres produits assimilés
  4. C)tous autres établissements en rapport avec son objet
  5. D)des magasins de gros et des départements de fabrication et d’analyse en rapport avec les activités énumérées ci-avant
  6. A)procéder à toutes opérations financières,acquérir par achat ou autrement valeurs mobilières,créances,parts et participations,gestion portefeuille ou capitaux,caution,aval ou garanties
  7. B)s’intéresser par apport,fusion,souscription,commandite ou autres dans entreprises,associations ou sociétés dont objet similaire,analogue,connexe ou utile
  8. C)effectuer opérations et études sur biens ou droits immobiliers par nature,incorporation ou destination et mobiliers en découlant,acheter,construire,transformer,aménager,louer,sous-louer,échanger,vendre,gestion ou mise en valeur pour soi ou autrui
  9. D)réaliser opérations industrielles,commerciales ou de service favorisant directement ou indirectement son objet
  10. E)pourvoir à administration,supervision et contrôle de sociétés liées ou en participation
  11. F)consentir prêts ou garanties sous quelque forme et durée à sociétés liées ou en participation si non réservé aux banques et organismes de crédit
deed of 29-03-2024 (in French)

Registered office and establishments

1 establishment
Establishment Since Unit numberFASFC approval
CITYPHARMA registered office Baraplein 2, 1070 Anderlecht 01-10-2008 2.173.692.301 Pharmacy (food >3 months)

Buildings and parcels at the address

Ground area
400 m²
Buildings
191 m²
Volume, LiDAR
2,266 m³
Tallest building
20.1 m
Buildings to scale, each on its own parcel
191 m², 20.1 m 191 m², 20.1 m

Location

registered office establishment The establishment unit on the map
3 companies at this address See who is registered here

Parcels

Cadastral parcelArea Buildings Height / floors
21305B0204/00A036400 m² 1 · 191 m² 20.1 m · 5

Recognitions

Food safety, FASFC

1 site
Anderlechtunit number 2.173.692.301
1 permission
Pharmacy (food >3 months) · since 19-05-2009

Source: FAVV-AFSCA, open data, updated on 02-11-2026

We would like to set cookies. That happens only with your consent. What we measure